Table 3.

Analysis 2: HIT outcome (studies from categories A and B)


Study or subcategory

Treatment-LMWH, n/N

Control-UFH, n/N

Weight, %

OR random (95% CI)
Leyvraz et al,11  1991   0/174   2/175   15.64   0.20 (0.01, 4.17)  
Warkentin et al, 1995   0/333   8/332   17.76   0.06 (0.00, 1.00)  
Ganzer et al,13  1999   0/325   10/307   17.95   0.04 (0.00, 0.75)  
Pouplard et al,14  1999   0/171   6/157   17.41   0.07 (0.00, 1.22)  
Mahlfeld et al,12  2002   1/252   5/252   31.23   0.20 (0.02, 1.70)  
Total (95% CI)
 
1255
 
1223
 
100.00
 
0.10 (0.03, 0.33)
 

Study or subcategory

Treatment-LMWH, n/N

Control-UFH, n/N

Weight, %

OR random (95% CI)
Leyvraz et al,11  1991   0/174   2/175   15.64   0.20 (0.01, 4.17)  
Warkentin et al, 1995   0/333   8/332   17.76   0.06 (0.00, 1.00)  
Ganzer et al,13  1999   0/325   10/307   17.95   0.04 (0.00, 0.75)  
Pouplard et al,14  1999   0/171   6/157   17.41   0.07 (0.00, 1.22)  
Mahlfeld et al,12  2002   1/252   5/252   31.23   0.20 (0.02, 1.70)  
Total (95% CI)
 
1255
 
1223
 
100.00
 
0.10 (0.03, 0.33)
 

Review: JLEE meta (version 01); comparison: 02 UFH versus LMWH; outcome: 02 HIT (RCT and prospective studies).

Total events for treatment-LMWH = 1; for control-UFH = 31. Test for heterogeneity: χ2 = 1.18, df = 4 (P = .88), I2 = 0%.

Test for overall effect: Z = 3/74 (P < .001).

Close Modal

or Create an Account

Close Modal
Close Modal